Is it Time to Update Societal Value Sets for Preference-Based Measures of Health? A. Simon Pickard Editorial 14 January 2015 Pages: 191 - 192
Resource Modelling: The Missing Piece of the HTA Jigsaw? Praveen ThokalaSimon DixonBeate Jahn Leading Article 20 November 2014 Pages: 193 - 203
A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis Mickaël HiligsmannSilvia M. EversAnnelies Boonen Systematic Review 07 November 2014 Pages: 205 - 224
Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective Michael HolmesSarah DavisEmma Simpson Review Article 26 November 2014 Pages: 225 - 233
Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes? Heather McDonaldCathy CharlesAmiram Gafni Review Article 26 November 2014 Pages: 235 - 241
Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study Bohdan NosykViviane LimaJulio S. G. Montaner Original Research Article 18 November 2014 Pages: 243 - 253
Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework Mike PauldenTania StafinskiChristopher McCabe Original Research Article Open access 21 November 2014 Pages: 255 - 269
Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation Alexander MenschStephanie StockDirk Müller Original Research Article 18 November 2014 Pages: 271 - 283